24 Jul, EOD - Indian

SENSEX 80148.88 (-0.35)

Nifty 50 24413.5 (-0.27)

Nifty Bank 51317 (-0.89)

Nifty IT 40115.05 (0.18)

Nifty Midcap 100 56872.75 (1.04)

Nifty Next 50 71844.65 (0.30)

Nifty Pharma 20908.5 (0.74)

Nifty Smallcap 100 18723.5 (1.76)

24 Jul, EOD - Global

NIKKEI 225 39154.85 (-1.11)

HANG SENG 17311.05 (-0.91)

DOW JONES 40022.43 (-0.83)

S&P 5459.08 (-1.74)

Login/Signup

Ajanta Pharma Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 532331 | NSE Symbol : AJANTPHARM | ISIN : INE031B01049 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose
17-Jul-2024 30-Jul-2024 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2024 inter alia to consider and approve unaudited consolidated and standalone financial results of the Company for the first quarter ended 30th June 2024.
22-Apr-2024 02-May-2024 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 inter alia to consider and approve a. Audited Financial Results (consolidated & standalone) of the Company for the quarter and year ended 31st March 2024; and b. Audited Financial Statements (consolidated & standalone) for the year ended 31st March 2024. AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 ,inter alia, to consider and approve Pursuant to Regulation 29(1)(b) of the Listing Regulations and in continuation to our intimation dated April 22, 2024 about meeting of the Board of Directors of the Company scheduled to be held on Thursday, May 2, 2024, we hereby inform that at the said meeting, the Board will also consider a proposal for buy-back of Equity Shares of the Company and other matters incidental and necessary thereto, in accordance with the applicable provisions of the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws (As Per BSE Announcement Dated on 26-04-2024) We hereby inform that at the Board meeting held on Thursday, 2nd May 2024, Board has inter-alia approved the following: 1. Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2024. 2. Proposal of Buy Back. PFA enclosed outcome of Board Meeting for more details. Pursuant to Regulation 30 of SEBI (LODR), we hereby inform that at the Board Meeting held today, the Board approved appointment of following persons as Additional Non-Executive Independent Director subject to approval of members: 1. Mr. David Rasquinha 2. Mrs. Medha Joshi 3. Mr. Rajesh Dalal 4. Mrs. Simi Thapar Pls find enclosed details towards: 1. Appointment of Cost Auditors 2. Vacancy of Cost Auditors 3. Re-appointment of Secretarial Auditors 4. Re-appointment of Tax Auditors We hereby inform that at the Board meeting held on Thursday, 2nd May 2024, Board has inter-alia approved the following: 1. Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2024. 2. Proposal of Buy Back. PFA enclosed outcome of Board Meeting for more details. Outcome of Board Meeting (As Per BSE Announcement Dated on 02.05.2024) In our intimation dated 2nd May 2024, under Regulation 30 of SEBI (LODR) Regulations, 2015, we had inadvertently intimated about change of Cost Auditor. PFA correct intimation for change in cost auditors. (As Per BSE Announcement Dated on 03/05/2024) PFA Board Resolution for Buy Back (As Per BSE Announcement Dated on 06.05.2024)
19-Jan-2024 31-Jan-2024 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 inter alia to consider and approve Unaudited Consolidated and Standalone Financial Results for the third quarter ended 31.12.2023. AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 ,inter alia, to consider and approve This is with reference to our letter dated 19th January 2024, informing about the Board meeting scheduled on Wednesday, 31st January 2024 to inter-alia consider and take on record the unaudited financial results for the third quarter ended 31st December 2023. Pursuant to Regulation 29(1)(e) of the Listing Regulations, we hereby inform that, at the aforesaid Board Meeting, the Board of Directors will also consider: a. declaration of 2nd interim dividend for the financial year ending 31st March 2024; b. fixation of Thursday, 8th Dec 2024 as the Record Date for the payment of 2nd interim dividend, if declared. (As Per BSE Announcement Dated on 24.01.2024) The Board in its meeting held today has approved 2nd Interim Dividend. For more details please find enclosed herewith outcome of the Board Meeting. At the Board meeting held today, the Board has inter-alia approved and took on record Unaudited Financial results for the quarter and nine months ended 31st December 2023, pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 31.01.2024)
19-Oct-2023 31-Oct-2023 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2023 inter alia to consider and approve Unaudited Consolidated and Standalone Financial Results for the second quarter and half year ended 30.09.2023 Results for the Second Quarter and Half Year Ended 30th September 2023. PFA herewith results for H1 FY 2024 (As per BSE Announcement Dated on 31/10/2023) Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the quarter ended 30th September 2023 published in the following newspapers on 1st November 2023: 1. Mumbai edition of Business Standard and 2. Mumbai edition of Navakal (As Per BSE Announcement Dated on 01/11/2023)
14-Jul-2023 27-Jul-2023 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2023 inter alia to consider and approve unaudited consolidated and standalone financial results of the Company for the first quarter ended 30th June 2023. AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2023 ,inter alia, to consider and approve This is with reference to our letter dated 14th July 2023, informing you about the Board meeting scheduled on Thursday, 27th July 2023 to inter-alia consider and take on record the unaudited financial results for the first quarter ended 30th June 2023. Pursuant to Regulation 29(1)(e) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider proposal for: a. declaration of interim dividend, if any, for the financial year ending 31st March 2024; and b. fixation of Friday, 4th August 2023 as the Record Date for the payment of interim dividend, if declared. Board to consider interim dividend at the meeting held on Thursday, 27th July 2023. (As Per BSE Announcement Dated on 24.07.2023) Board approved:- 1. First Interim dividend of Rs. 315 cr. for the year FY 2024. It translates into Rs. 25 per share (1250%) on face value ofRs. 2/- per share. This total dividend ofRs. 25 per share includes a regular dividend ofRs. l0 per share, and an additional Rs. 15 per share, distributed as a special dividend on the commemoration of 50 years of momentous joumey of the Company. 2. Fixed Friday, 4e August 2023 as the Record dale for payment of interim dividend and special dividend. Dividend will be paid on or after I ls August 2023. (As Per BSE Bulletin Dated on 27.07.2023) Outcome of Board Meeting (As per BSE Announcement Dated on 27/07/2023)
27-Apr-2023 05-May-2023 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2023 inter alia to consider and approve a. Audited Financial Results (consolidated & standalone) of the Company for the quarter and year ended 31st March 2023; and b. Audited Financial Statements (consolidated & standalone) for the year ended 31st March 2023. We hereby inform that at the Board meeting held on Friday, 5th May 2023, Board has inter-alia approved and taken on record the Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2023. Board has also approved amendment in the object clause of Memorandum of Association (MOA) to align the same with regulatory requirements. There is no change in the principal business of the Company. This amendment is subject to approval of the shareholders at the ensuing Annual General Meeting. (As Per BSE Announcement Dated on 05.05.2023) Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the quarter and year ended 31st March 2023 published in the following newspapers on 6th May 2023: 1. Mumbai edition of Business Standard and 2. Mumbai edition of Navakal. This is for your information and record. (As Per BSE Announcement Dated on 07.05.2023)
06-Mar-2023 10-Mar-2023 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/03/2023 inter alia to consider and approve the proposal for buyback of the equity shares of the Company and matters related / incidental thereto. The Board of Directors of the Company, at its meeting held today, i.e., March 10, 2023, has inter-alia considered and approved Buyback of 22,10,500 fully paid-up Equity Shares of face value of ? 2/- each by the Company (representing 2.59% of the total number of Equity Shares of the Company as of March 31, 2022 (not adjusted for bonus issue undertaken by Company as on June 24, 2022 ) at a price of ? 1,425/- (Indian Rupees One Thousand Four Hundred Twenty Five only) per Equity Share payable in cash for a total consideration not exceeding ? 315 crores (Indian Rupees Three Hundred and Fifteen crores only) (excluding transaction costs such as fees, brokerage, taxes, duties, etc.), which represents 9.93% and 9.64% of the aggregate of the Company's paid-up capital and free reserves as per the standalone and consolidated audited financials of the Company for the year ended as on March 31, 2022 respectively. We wish to inform you that in accordance with Regulation 42 of the Listing Regulations and Regulation 9(i) of the SEBI (Buy-Back of Securities) Regulations, 2018, as amended, the Buyback Committee of the Company, being duly authorised by the Board of Directors of the Company in this regard, have at their meeting held on March 10, 2023, considered and approved the record date for the proposed Buy-back offer as Friday, March 24, 2023. (As Per BSE Announcement dated on 10.03.2023)
23-Jan-2023 01-Feb-2023 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2023 inter alia to consider and approve unaudited consolidated & standalone financial results of the Company for the third quarter and nine months ended 31st December 2022. At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited Financial results for the quarter and nine months ended 31st December 2022. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that based on the recommendations of Nomination & Remuneration Committee meeting held today, Board has also approved the re-appointment of Mr. Yogesh Agrawal as Managing Director and Mr. Rajesh Agrawal as Joint Managing Director for a further period of five years from 1st April 2023 upto 31st March 2028, subject to approval of members. Results for the quarter and nine months ended 31st December 2022 (As per BSE Announcement Dated on 01/02/2023)
21-Oct-2022 03-Nov-2022 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2022 inter alia to consider and approve unaudited consolidated & standalone Financial Results of the Company for the second quarter and half year ended 30th September 2022. Quarterly Results & Interim Dividend (As Per BSE Bulletin Dated on 31.10.2022) AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2022 ,inter alia, to consider and approve This is with reference to our letter dated 21st October 2022, informing you about the Board meeting scheduled on Thursday, 3rd November 2022 to inter-alia consider and take on record the unaudited financial results for the second quarter and half year ended 30th September 2022. Pursuant to Regulation 29(1)(e) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider proposal for: a. declaration of interim dividend, if any, for the financial year ending 31st March 2023; and b. fixation of Monday, 14th November, 2022 as the Record Date for the payment of interim dividend, if declared. You are requested to please take a note of the same and disseminate to all concerned. This is with reference to our letter dated 21st October 2022, informing you about the Board meeting scheduled on Thursday, 3rd November 2022 to inter-alia consider and take on record the unaudited financial results for the second quarter and half year ended 30th September 2022. Pursuant to Regulation 29(1)(e) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider proposal for: a. declaration of interim dividend, if any, for the financial year ending 31st March 2023; and b. fixation of Monday, 14th November, 2022 as the Record Date for the payment of interim dividend, if declared. You are requested to please take a note of the same and disseminate to all concerned. (As Per BSE Announcement Dated on 31.10.2022) Pursuant to Regulations 33, 42 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Board of Directors of Company have at their meeting held on 3rd November 2022, approved the following: i. Unaudited Consolidated and Standalone Financial Results of the Company for the second quarter and half year ended 30th September 2022; ii. Payment of interim dividend of Rs. 7/- (350%) per equity share on the face-value of Rs. 2/- per share for the Financial Year 2022-23; iii. Fixed Monday, 14th November 2022 as the Record date for payment of interim dividend. Interim dividend will be paid on or after 24th November 2022. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the record date for taking record of the Members of the Company for the purpose of determination of shareholders to whom interim dividend would be payable would be Monday, 14th November 2022. Results for second quarter and half year ended 30th September 2022 (As Per BSE Announcement Dated 03.11.2022)
20-Jul-2022 28-Jul-2022 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2022 inter alia to consider and approve Unaudited consolidated and standalone financial results of the Company for the first quarter ended 30th June 2022. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following: i. Press Release being issued on the Results for the quarter ended 30th June 2022; ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2022; iii. Limited Review Report from Auditors, M/s B S R & Co. LLP, on the unaudited Consolidated Financial Results for the quarter ended 30th June 2022; iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2022; v. Limited Review Report from Auditors, M/s B S R & Co. LLP, on the unaudited Standalone Financial Results for the quarter ended 30th June 2022; vi. Investors' presentation. Kindly note that the meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 3.50 p.m. and take the above on your records. At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited Financial results for the quarter ended 30th June 2022. Pursuant to Regulation 33 of SEBI LODR Regulations, 2015, we enclose herewith the following: i. Press Release being issued on the Results for the quarter ended 30th June 2022; ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2022; iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2022; iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2022; v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2022; vi. Investors' presentation. Kindly note that the meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 3.50 p.m. and take the above on your records. (As Per BSE Announcement dated on 28.07.2022)
02-May-2022 10-May-2022 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2022 inter alia to consider and approve Pursuant to Regulation 29 of the Listing Regulations we hereby inform that a Meeting of the Board of Directors of the Company will be held on Tuesday 10th May 2022 to inter-alia consider: a. Audited Financial Results (consolidated & standalone) of the Company for the quarter and year ended 31st March 2022; b. Audited Financial Statements (consolidated & standalone) for the year ended 31st March 2022 and c. Issue of bonus shares subject to approval by the shareholders of the Company. We hereby inform that at the Board meeting held on Tuesday, 10th May 2022, the Board has interalia: a. Approved and taken on record, Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2022; b. Approved issue of bonus shares in the ratio of 1:2 i.e. One new fully paid-up equity shares of Rs. 2/- each to be issued for every Two equity shares held, subject to approval of shareholders of the Company. Separate disclosure under Regulation 30 is being filed shortly; c. Recommended re-appointment of M/s. B S R & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022) as statutory auditors of the Company for second term of 5 years, from the conclusion of 43rd Annual General Meeting till the conclusion of 48th Annual General Meeting, subject to the approval of the shareholders of the Company. Pursuant to Regulation 30 of the Listing Regulations, we hereby inform that the Board has approved obtaining shareholders' approval by postal ballot for issue of bonus shares. For dispatch of postal ballot notice, company shall be taking beneficiary position as on 11th May 2022. The Company shall further intimate the Stock Exchanges on completion of dispatch of the Postal Ballot notice. (As Per BSE Announcement Dated on 10.05.2022)
21-Jan-2022 31-Jan-2022 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022 inter alia to consider and approve We hereby inform that a Meeting of the Board of Directors of the Company will be held on Monday 31st January 2022 to inter-alia consider and approve unaudited consolidated & standalone financial results of the Company for the third quarter ended 31st December 2021. You are requested to please take a note of the same and disseminate to all concerned.
23-Dec-2021 28-Dec-2021 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/12/2021 inter alia to consider and approve Pursuant to Regulation 29(1)(b) of the Listing Regulations we hereby inform that meeting of the Board of Directors of the Company is scheduled on Tuesday 28th December 2021 to consider a proposal for buy-back of equity shares including matters related /incidental thereto. Board of Directors of the Company, at its meeting held today, i.e., December 28, 2021, has inter-alia unanimously approved Buy-back of up to 11,20,000 fully paid-up Equity Shares of face value of ? 2/- each by the Company (representing 1.29%of the total number of Equity Shares of the Company) at a price of ? 2,550/- (Rupees Two Thousand Five Hundred and Fifty only) per Equity Share payable in cash for a total consideration not exceeding ? 285.60 crores (Rupees Two Hundred Eighty Five Crores and Sixty Lakhs only) (excluding transaction costs such as fees, brokerage, taxes, duties, etc.), which is not exceeding 10% of the total paid-up equity share capital and free reserves (including securities premium account) as per the audited financial statements of the Company for the financial year ended on March 31, 2021, through the 'Tender Offer' route. (As per BSE Announcement Dated on 28/12/2021)
21-Oct-2021 29-Oct-2021 Interim Dividend & Quarterly Results AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Listing Regulations, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Friday, 29th October 2021 to inter-alia: 1. Approve and take on record unaudited consolidated & standalone Financial Results of the Company for the second quarter and half year ended 30th September 2021 and 2. Consider declaration of interim dividend, if any, for the financial year ending 31st March 2022. 3. Fixation of Wednesday, 10th November 2021 as the Record Date for the payment of interim dividend, if declared. You are requested to please take a note of the same and disseminate to all concerned. Ajanta Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 29, 2021, inter alia, has approved the following: - Payment of interim dividend of Rs. 9.50/- (475%) per equity share on the face-value of Rs. 2/- per share for the Financial Year 2021-22. lnterim dividend will be paid on or after November 16, 2021. Dear Sir/Madam, Pursuant to Regulations 33, 42 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Board of Directors of Company have at their meeting held on 29th October 2021, approved the following: i. Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended 30th September 2021; ii. Payment of interim dividend of Rs. 9.50/- (475%) per equity share on the face-value of Rs. 2/- per share for the Financial Year 2021-22; iii. Fixed Wednesday, 10th November 2021 as the Record date for payment of interim dividend. lnterim dividend will be paid on or after Tuesday, 16th November 2021. Kindly note that the meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 2.15 p.m. and take the above on your records. Kindly take the above on your records. (As Per BSE Announcement Dated on 29.10.2021)
21-Jul-2021 29-Jul-2021 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Listing Regulations, we hereby inform that a Meeting of the Board of Directors of the company will be held on Thursday. 29th July 2021, to inier-alia, consider and approve unaudited consolidated and standalone financial results of the Company for the first quarter ended 30th June 2021. At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited Financial results for the quarter ended 30th June 2021. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following: i. Press Release being issued on the Results for the quarter ended 30th June 2021; ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2021; iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2021; iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2021; v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2021; vi. Investors' presentation. (As Per BSE Announcement dated on 29.07.2021)
1 2 3  Next